L. Hartmann

Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development.

M. Foley, J. Ingle, P. Roche, 1999, Neoplasia.

Systemic adjuvant therapy in women with resected node-negative breast cancer.

D. Schaid, J. Ingle, L. Hartmann, 1991, Mayo Clinic proceedings.

p16 Expression and Breast Cancer Risk in Women with Atypical Hyperplasia.

R. Vierkant, L. Hartmann, H. Berman, 2009 .

Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience.

A. Weaver, J. Donohue, J. Ingle, 1994, Mayo Clinic proceedings.

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

C. Conover, C. Erlichman, V. Suman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of Ifosfamide Plus Mesna as First‐Line Chemotherapy in Women with Metastatic Breast Cancer

J. Ingle, J. Krook, H. Wieand, 1995, American journal of clinical oncology.

Granulocyte‐macrophage colony‐stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin

L. Hartmann, J. Edmonson, J. A. Jefferies, 1992, Cancer.

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

Shailendra Giri, V. Shridhar, L. Hartmann, 2009, Journal of cellular and molecular medicine.